
Presenting Companies
December 2022 Conference

Founded in 2020, Alyra has developed a platform focused on developing drugs that block protein–protein interactions (PPIs) - highly specific physical contacts between proteins that play a role in diseases such as cancer, autoimmune disease and neurodegenerative disorders. Our lead program ALY101 blocks the interactions of proteins involved in activating a protein called PAK1 which drives tumor growth and blood vessel formation across a range of cancers. ALY101 has shown activity in multiple cancer types in vitro and in vivo in a mouse melanoma model. We are raising a $2 M dollar seed round to: (1) advance development of ALY101, (2) advance another program with applications in cancer and Parkinson’s disease and (3) further refine our platform to explore additional therapeutic applications outside of cancer and neurodegenerative disease.
.png)
Avstera Therapeutics is an oncology-focused biotech company located in the Philadelphia area dedicated to addressing the large disease burden and significant unmet needs of advanced cancer patients. With a focus on foundational tumor biology science, Avstera leverages cutting-edge approaches to tackle key immunological challenges seen in the tumor microenvironment. Avstera also is proud to be collaborating with top cancer researchers at both Georgetown University and the University of Pennsylvania.

Bectas Therapeutics Inc. is biotech company that is bringing biomarker-based precision to immune oncology. Bectas was founded based on unique insights from human cancer patients treated with existing standard of care immunotherapy that was licensed from Apricity Health and validated by the published work of Nobel Laureate Dr. James Allison, a member of Apricity’s scientific advisory board. These real-world patient insights identified three myeloid targets driving resistance to current T cell checkpoint immune therapy in cancer. Bectas has developed patient selection biomarkers and identified fully human monoclonal antibodies with drug-like profiles for the lead program and is on track to select a clinical development candidate in 1H2023. The world-class team includes seasoned biotech executives, accomplished drug developers, experienced entrepreneurs, and world-leading physician scientists and precision medicine experts.

Bespoke is a cellular immunotherapy start-up built-upon NIH and NSF grant funding, a robust B-cell gene editing patent portfolio, and a leadership team composed of cell therapy product development experts. Bespoke is developing proprietary human B-cell non-viral genome engineering and synthetic biology technology platforms as well as innovative engineered B-cell therapeutic products for patients at high risk of relapse or already with metastatic solid tumor cancers. Central to our technologies and product candidates is engineering to create B-cells that only express and secrete immunomodulatory and anticancer protein payloads (e.g., antibodies and interleukins) after stimulation of engineered B-cell receptors by a specific tumor-associated antigen. This B-cell receptor “on-switch” and actuated (i.e., inducible) payload delivery focuses therapy at sites of active disease and prevents dose-limiting and serious systemic off-tumor toxicity. Current pre-clinical research and process development will support an IND for a first-in-human study of autologous B-cell therapeutics in women with advanced breast cancer.

BioTwin harnesses AI, biomarkers and biometrics to create a virtual human copy. These digital twins allow early detection & prediction of diseases and innumerable simulations. Through a “toolbox” ecosystem, this technology is revolutionizing the wellness & healthcare fields by making personalized & preventive medicine a reality.

Based in Vancouver, BioVaxys Technology Corp. (www.biovaxys.com) is a British Columbia- registered, clinical-stage biotechnology company that is developing viral and oncology vaccines based on a proprietary haptenized antigen technology platform that is highly scalable for any resectable tumor, and with supporting clinical data in over 600 subjects. BioVaxys currently has an immunotherapeutic vaccine for Stage III/Stage IV platinum-resistant ovarian cancer entering clinical trials in the EU in 2023, and a colorectal cancer vaccine in late preclinical development. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF).

BlueSky Immunotherapies is a European clinical stage life science firm, developing its interferon inducing vector delNS platform against solid cancers & infectious and allergic diseases. The company is in a phase 1 clinical trial against HPV16 induced cervical cancers and lesions and has successfully reached the primary endpoints safety and tolerability. In addition, BlueSky can present excellent efficacy data from this clinical trial. BlueSky Immunotherapies has started reach-out to investors for a Series A financing round of $15m-20m to carry out subsequent clinical trials phase II.

CairnSurgical, Inc. is an early commercialization growth stage company that has developed a platform technology to improve surgical outcomes with image-derived, 3-D printed surgical guides. Our first product is a breast cancer surgery guide, commercial in EU and clinical stage in US. The Breast Cancer Locator™ System (BCL™) is a proprietary, patient-specific, surgical guidance system designed to achieve clear margins.

Canget BioTekpharma is an innovative drug development company committed to advancing a NEW class of oncology products that eliminate cancer and address multiple mechanisms of drug resistance. Our portfolio of products are the targeted small molecules, not cytotoxic drugs, and our lead drug FL118 is a Triple Target Inhibitor of known drug resistance pathways - DDX5 / USP2a / UbE2T. Our lead product FL118 has demonstrated high efficacy in pancreatic, colorectal, and prostate cancers, and exhibited favorable safety profiles in multiple animal models (mice, rats, dogs).

CasInvent Pharma is an early-stage drug discovery company, and our mission is to bring novel class of Casein Kinase 1 inhibitor drug for the treatment of leukaemia’s and solid tumours to the market. The small-molecule lead compound exhibits exceptional selectivity to the targeted isoforms of Casein kinase 1 (CK1), combined with favorable oral pharmacokinetic and safety profiles.

Chimera’s GOLD technology is rooted in the observation that natural T lymphocytes are adept at controlling when and where they produce potent anti-tumor proteins called cytokines. They have discovered important details about how natural T cells control cytokine production, and have used this understanding to design engineered CAR-T cells that produce extremely potent anti-tumor proteins, like Interleukin-12 (IL-12), only upon interaction with a tumor. CAR-T cells armed with IL-12 controlled by the GOLD technology produce complete responses in preclinical models of pancreatic adenocarcinoma, metastatic prostate cancer, and triple-negative breast cancer.

Founded in 2022, ConjugateBio Inc. is an ADC (antibody-drug-conjugate) company with three in-licensed assets. Our lead asset, CNJ-001, has shown great safety and efficacy profile in multiple mice PDX/CDX models of SCLC and neuroblastoma. We intend to build 3 different linker-payload constructs, to test them in-vitro and in-vivo, to finally move the final candidate into non-GLP monkey tox. Our second asset, CNJ-002, has proven effect in mice xenograft as naked antibody for NSCLC, ovarian and pancreatic cancers. We intend to do further characterization studies and build an ADC. Our third asset is exclusive option by target to proprietary linker-payload systems that includes a pH sensitive linker and a protease sensitive linker with top1 inhibitor as payload. We’re raising a $6.5M dollar seed round to advance our lead asset, CNJ-001 to a final candidate with non-GLP monkey tox, along with characterization work for our second asset.

Curadigm is a French early-stage nanotechnology company dedicated to improving outcomes for patients by shifting the therapeutic delivery paradigm. Curadigm’s Nanoprimer technology is designed to transiently occupy the liver pathways involved in the clearance of nanomedicine-based therapeutics in order to increase their blood bioavailability while decreasing unintended off-target effects, specifically liver toxicity. The Nanoprimer technology has been validated in combination with different products including nucleic acid-based therapeutics.

Elpis is a clinical stage company, developing fully human bispecific armored allogeneic CAR-NK and CAR-γδ T cell therapies to treat cancer patients. We have developed the KIMM-ALLO™ platform that enables engineering and development of multi-feature allogeneic cell therapy as a single product through a unique modular combination with desired mechanisms. KIMM-ALLO™ platform has incorporated proprietary KIL2™ and BIT™ technology to potentiate effective and durable patient response. Elpis is advancing a rich pipeline of best and first-in class programs into clinic, targeting hematological malignancies and solid tumors with high unmet medical needs, e.g., squamous cell lung cancer, pancreatic cancer, glioblastoma, relapsed/refractory multiple myeloma, relapsed/refractory acute myeloid leukemia, etc.

Enterome is a clinical stage company developing off-the-shelf, transformational cancer treatments targeting all tumor types. Ongoing Phase 2 trials for our most advanced program EO2401 have shown promising efficacy in recurrent glioblastoma and adrenal malignancies and good safety in more than 130 patients. Enterome’s OncoMimics™ approach generates a powerful, long-lasting immune response from the patient’s own effector memory T-cells, overcoming the immune tolerance to self-antigens. With 5 clinical immune-oncology projects to date, our fully integrated R&D platform has the potential to deliver multiple candidates with a rapid progression “from bench to bed”. In addition to OncoMimics™ programs, Enterome has also established partnerships with Takeda and Nestlé Health Science in IBD and food allergy.

Humanetics is a clinical-stage drug development company focused on improving outcomes for cancer patients receiving radiotherapy. Humanetics’ lead compound, BIO 300, is a small molecule oral therapeutic that can be safely added to standard of care to mitigate common radiotherapy-induced side-effects while improving the therapeutic index. Strong data supports its use across a broad range of cancers including lung, prostate, brain and head and neck. Nearly half of all patients with solid tumors receive radiotherapy, and BIO 300 would be a first in class drug with the potential to improve outcomes in these patients. BIO 300 has additional indications in acute radiation syndrome and inflammatory diseases including COVID-19.

Innova Therapeutics is a Charleston, South Carolina-based biotechnology company developing a monoclonal antibody (mAb) platform that targets a highly expressed protein in various solid cancers and has shown to correlate with patient outcomes. The lead humanized mAb has been selected and designated as IVT-8086. Innova’s initial platform technology is focused on targeting cancers, including pediatric osteosarcoma, sarcomas, triple-negative breast cancer, and pancreatic cancer, but has broad benefit across most solid and hematological tumors. The focus on pediatric osteosarcoma will allow fast-regulatory approval. Osteosarcoma is a rare disease that was granted both orphan designation and rare pediatric disease designation from the FDA. This will expedite the regulatory approval timeline, including the opportunity to obtain a Rare Pediatric Disease priority review voucher. Because Priority Review Vouchers (PRVs) may be sold, a secondary market for the vouchers has emerged with revenue ranging between $80M and $350M.

LabyRx is a clinical-stage immuno-oncology company focused on novel therapeutic vaccines and antibodies. Preclinical development of antibody-based anti-adenocarcinoma agents is under way, e.g., human(ized) antibodies, CAR-T/-M. Our initial vaccine clinical trial, performed in concert with the University of California NCI-Designated Cancer Center, Davis, is near completion.

Leapfrog Bio is a venture-backed, near clinical-stage biotechnology company developing novel targeted therapies for orphan oncology indications. We are addressing the approximately two-thirds of cancers that are driven by loss of function mutations which cannot be targeted with conventional approaches. Our clinically validated pharmacogenomic platform identifies synthetic lethality relationships between the genetic mutations driving particular cancers and the biological targets of shelved clinical stage compounds. Leveraging the existing clinical and pre-clinical data relating to these compounds, we intend to initiate Phase 2 clinical trials evaluating the compounds in cancers where the relevant mutation is prevalent and there is a high unmet clinical need with the goal of obtaining If successful, this approach will allow for the accelerated approval of the compounds in select orphan oncology indications.

LINK is engaged in the discovery and development of highly differentiated T-cell engagers. These next-generation immunotherapies will safely redirect T cells to tumors to promote durable patient responses by leveraging T-cell costimulation and selective combination strategies. The company's lead program is on track for an IND in Q2, 2023. LINK aspires to be the leading developer of novel multispecific T-cell engagers.
The name of our company, Malignant Tumor Treatment Technologies (M.T.3), reflects our desire to continue researching and providing treatment techniques for malignant tumors. Our current core product is a compound derived from marine organisms. This compound is expected to be a novel radiosensitizer because it shows radiosensitizing effects even at low doses, and has low degrees of toxicity and other side effects. We are beginning to explore human medicine applications as we believe our compounds can be fully utilized in such fields.


Nami Therapeutics Corporation (’Nami’) is an innovative radiopharmaceutical company developing tumor-specific precision therapeutics. The first product is on treating metastatic ovarian cancer, the No. 1 cause of death from gynecological malignancies, the survival rate of which remains 29% despite the introduction of new therapies. To address this unmet medical need, Nami has developed XLNT-1, a specifically designed nanoparticle containing a therapeutic radioisotope. Selective accumulation in peritoneal tumors and extended survival has been demonstrated in preclinical studies following intraperitoneal administration of XLNT-1. This platform technology enables XLNT-1 to be used for other cancers such as pancreatic, GI and prostate cancers.

Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of many types of cancers, producing durable therapeutical efficacy in advanced- stage tumors. Nonetheless, most cancer patients do not benefit from these therapies. Neomics is developing novel Immune Checkpoint Switching T (ICS T) cell therapy to extend the immunotherapy benefit to patients far and beyond.

NuvOx Pharma is a biotechnology company based in Tucson, Arizona that is developing a first-in-class oxygen therapeutic to treat life-threatening diseases where hypoxia plays a role. Over 30 animal studies have shown therapeutic effect in seven different indications. Phase Ib/II clinical trials in stroke and oncology demonstrated safety and evidence of efficacy, and the company is preparing to run a Phase IIa trial in COVID-19 patients with Acute Hypoxemic Respiratory Failure (AHRF).

Olive Healthcare is a company that measures and analyzes biomarkers based on multi-wavelength near-infrared technology and provides various predictive model services related to cancer, muscle, and metabolic syndrome., etc. Devices and services that manage health and body shape through muscle and fat indexes have been commercialized and are already being sold in the wellness market. Currently, the company has successfully completed clinical trials on a device that accurately diagnoses breast cancer in the early stage and has taken steps towards commercialization.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova’s novel, proprietary multi-kinase inhibitor narazaciclib (formerly ON 123300) is being evaluated in two separate and complementary Phase 1 dose-escalation and expansion studies. These trials are currently underway in the United States and China. Onconova’s product candidate rigosertib is being studied in an investigator-sponsored study program, including in a dose-escalation and expansion Phase 1/2a investigator-sponsored study with oral rigosertib in combination with nivolumab for patients with KRAS+ non-small cell lung cancer.

Propelle is developing novel biopharmaceuticals and nucleic acid components for unmet medical challenges in targeting early inflammation within the tumor microenvironment to rebalance the immune system and allow the immunity cycle to reduce, shrink or eliminate the tumor by itself.

Rapa Therapeutics is a developer of a healthcare technology platform intended to cure cancer and autoimmune diseases. The company is working on a series of cutting-edge technologies focused on curing cancer, neurodegenerative and autoimmune diseases with the help of cell therapy, thereby helping patients to cure their diseases with medical technology.

Revere is a Boston-based, oncology-focused biotech company led by an experienced biopharma team. We are the leaders in developing Rac1 and other Rho (RAS homologous) GTPase inhibitors for treating cancer. Our proprietary platform for identifying small molecule Rac1 inhibitors is unique in the industry and is enabling development of a drug pipeline to address areas of high, unmet needs for cancer patients. We expect to designate our first development candidate in 2023 and file an IND in 2024.

Savor Health is a precision nutrition company that applies the science of nutrition to the optimization of the treatment of cancer and other complex medical conditions to improve health outcomes and reduce cost of care. Through a proprietary expert Platform designed to replicate the logic and knowledge of registered dietitians (“RDs”), Savor Health’s virtual Triage Nurse Function determines patient appropriateness for RD support and triages them to their medical provider or to the Company’s virtual Dietitian-on-Demand (Ina®) who provides 24/7 “on demand” evidence-based nutrition support via SMS text. Launched with pharma clients in 2019 for chemotherapy and immunotherapy symptom self management to improve adherence to their therapies, the Company's market leading results include 65% engagement, 70% utilization, 83% satisfaction and a robust, rapidly growing database of PRO and other real world data.

Senex Biotechnology is a drug discovery and development company focused on cancer therapeutics. Senex’s lead program targets a protein that regulates gene expression and is required by cancer cells to adapt to adversarial conditions; such adaptation leads to cancer drug resistance and metastasis. Senex is developing highly selective small-molecule inhibitors of this protein for the treatment of presently incurable types of prostate cancer, breast cancer and leukemia. We are also investigating the utility of these inhibitors for different cancers in combination with other therapeutics, as well as for inflammation, cardiovascular and other diseases. Our latest, highly potent and selective drug candidate is anticipated to enter clinical trials within a year. In addition to our lead program, Senex is developing drugs aimed at two other unique cancer targets.

SmartBreast Corp. is privately held with headquarters near Pittsburgh and offices in Los Angeles and Taipei, Taiwan (eveclearscan.com and smartbreast.com are under construction). It is a subsidiary of privately held EVO WorldWide, LLC (evo-worldwide.com) that distributes MBI globally. SmartBreast was founded in 2019 by Bradley Patt, PhD (Board Chair, Los Angeles), Prof. Chin-Tu Chen, PhD (Board Vice-Chair, Chicago), and James Hugg, PhD (CEO, Pittsburgh), each of whom has 30+ years' experience in medical imaging. SmartBreast manufactures molecular breast imaging (MBI) scanners for dense breasts under the brand name EVE CLEAR SCAN™, which along with SmartBreast™, EVE SCAN™, and the EVE owl logo are trademarks of SmartBreast Corporation.

Starpax Biopharma Inc. has developed a disruptive technology for precise 3D guidance of Magnetodrones™ into tumors. Magnetodrones are unique proprietary self-propelled bacteria (Bn1-S™) that are sensitive to magnetic fields and carry on their surface liposomes loaded with FDA-approved anti-cancer drugs. Patients are installed in the PolarTrak™ (a Starpax medical device) and the Magnetodrones are injected directly into the tumor. Using special proprietary magnetic field technology, the PolarTrak is designed to prevent the Magnetodrones from leaving the tumor and guides them in 3D, making them spread throughout the volume of the tumor and accumulating in the hypoxic zones which are hard to reach with other cancer treatments, while also not allowing the drug to circulate in the bloodstream. Preclinical studies have shown 1) a 100% remission rate, 2) no side effects or organ damage observed, 3) drug dispersion throughout the volume of the tumor and accumulation in the hypoxic zones.

SynDevRx lead drug evexomostat (SDX-7320) is in two Phase 2 clinical studies for metastatic breast cancer – in TNBC in combination with Haloven® (eribulin, Eisai) through a collaboration with Memorial Sloan Kettering and in HR+/HER2- combined with Piqray® (alpelisib, Novartis) and Faslodex® (fulvestrant, AstraZeneca). Preliminary data readouts are expected in mid-2023. The Phase 1 clinical safety study of evexomostat in late-stage cancer patients (avg. 6th line) showed clinically meaningful changes in key angiogenic biomarkers and metabolic hormones with and with anti-metastatic activity.

Tactical Therapeutics, Inc, is a clinical stage private company developing CTO, a First-in-class inhibitor of non-voltage calcium signaling and channels, with anti-proliferative, anti-angiogenic, anti-inflammatory, and anti-metastatic properties in preclinical and clinical studies. CTO is orally administered, has favorable bioavailability and brain-penetration, and inhibits multiple kinase pathways involved in cancer progression and drug resistance. Interestingly, preliminary studies suggest CTO inhibits calcium signaling involved in different stages of a viral cycle, including replication of SARS-CoV-2 in vitro.. CTO has been studied in three Phase I/IB trials for Safety at leading cancer centers including Oregon Health Sciences University and Memorial Sloan-Kettering Cancer Center. CTO alone or in combination radiation or chemotherapy (Temozolomide, TMZ) is safe, no grade 4or 5 adverse events reported In 44 cancer patients with different solid cancers, CTO monotherapy showed clinical benefit as durable stable disease up to 14 months in cancers with different mutations In 27 recurrent GBM patients, CTO plus TMZ showed 1 Complete and 8 Partial Responses including in tumors with resistant tumors (IDH/wt, EGFR, -ve MGMT) In 15 GBM patients with unresectable tumors, CTO with chemoradiation/adjuvant chemo, showed safety, efficacy, brain penetration, significantly improved Progression-free-survival (15 months) ant Overall Survival (OS)(28 months not reached). 62% OS at 24 months. Expected OS with unresectable tumors is 10 months. Given the high unmet need in GBM and CTO’s favorable clinical attributes, Key Opinion Leaders have expressed strong potential for CTO to be broadly used in GBM. End-of-Phase 1 meeting with FDA has been held and two Phase 2 trials randomized trials for recurrent GBA and newly diagnosed GBM are planned.

Thrive Bioscience’s instruments and software provide automated imaging and analytics of live cells and tissues for research and drug discovery. Thrive instruments automatically build extensive databases of terabytes of time-series images at 100 focal planes of all the cells in all the wells in cell culture plates.

TibaRay is an early stage company developing a new Radiation Therapy system that will treat cancer patients in a fraction of a second, resulting in dramatically reduced collateral damage to normal tissue leading to better outcomes. The well-patented enabling technological breakthroughs came out of the SLAC National Accelerator Lab and Stanford University Healthcare and uniquely position TibaRay to disrupt this $7B market by curing cancer in a FLASH.

Vetigenics is a clinical stage animal health biotech devoted to developing species specific cancer immunotherapies to improve and extend the lives of pets and by doing so, expand novel cancer treatment options for their humans. The company’s CANIBODY™ Platform technology utilizes a proprietary, entirely canine phage display platform together with unique panning techniques to rapidly isolate CANIBODIES™ (single chain variable fragments or scFvs) to any target antigen. Once selected, CANIBODIES™ can be easily formatted into a preferred therapeutic such as full-length monoclonal antibodies (mAbs), CAR-T or bi-specific antibodies. CANIBODIES have shown high affinity, good developability and functional characteristics with little to no engineering and once formatted, can be used directly in canine clinical studies. Results to date in canine studies demonstrate excellent safety, good biodistribution and lack of immunogenicity. Strategic partners include NCI, Merck Animal Health and a 2nd Major Animal Health Pharma, several academic research partnerships.